We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Catherine
Bagot
catherine.bagot@ggc.scot.nhs.uk
Dr
Catherine
Bagot
catherine.bagot@ggc.scot.nhs.uk
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
Blood clots in veins are the commonest cause of death in pregnant women. Overweight and obese pregnant women
have a greater chance of developing and dying from blood clots than normal weight pregnant women. National
guidelines recommend an increased dose of heparin in overweight and obese pregnant women to try and reduce this
increased risk. However, this has not been proven to be effective and it may increase the risk of bleeding, a known
side effect of heparin.
Our study will investigate why overweight and obese pregnant women have a higher risk of blood clots. It may be due
to an abnormality in the function and location of fat cells in the body. We will take blood from normal weight and
overweight pregnant women and test the blood to see how easily it clots and how fat cells work. We will measure the
amount of fat cells under the skin and around the abdominal organs using ultrasound, a test safe in pregnancy.
The study will be open to all pregnant women attending the Princess Royal Maternity Hospital, Glasgow. We will recruit
women of all body sizes and compare the results between normal weight, overweight and obese pregnant women.
Our study aim is to explain why overweight and obese pregnant women are at increased risk of blood clots. This
information should allow further studies to be performed to determine what heparin dose should be used to reduce
the risk of blood clots in overweight and obese pregnant women.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Not Specified;
You can take part if:
You may not be able to take part if:
Personal history of venous thrombosis A known major thrombophilia (protein C, S or antithrombin deficiency) Aged <18 Unable to give informed consent Unable to understand verbal or written English without the need for an interpreter Receiving therapeutic or prophylactic low molecular weight/unfractionated heparin at time of recruitment Multiple pregnancy
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Catherine
Bagot
catherine.bagot@ggc.scot.nhs.uk
Dr
Catherine
Bagot
catherine.bagot@ggc.scot.nhs.uk
The study is sponsored by GREATER GLASGOW AND CLYDE and funded by British Heart Foundation (BHF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 43019
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
